195 related articles for article (PubMed ID: 29029577)
1. A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption.
Wang T; Shen L; Zhang Z; Li H; Huang R; Zhang Y; Quan D
Drug Deliv; 2017 Nov; 24(1):1565-1573. PubMed ID: 29029577
[TBL] [Abstract][Full Text] [Related]
2. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
3. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
4. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
6. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers.
Venâncio JH; Andrade LM; Esteves NLS; Brito LB; Valadares MC; Oliveira GAR; Lima EM; Marreto RN; Gratieri T; Taveira SF
J Pharm Pharmacol; 2017 Oct; 69(10):1318-1326. PubMed ID: 28703281
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
8. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Su Y; Hu P; Lee SH; Sinko PJ
J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
[TBL] [Abstract][Full Text] [Related]
9. Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery.
Xing R; Mustapha O; Ali T; Rehman M; Zaidi SS; Baseer A; Batool S; Mukhtiar M; Shafique S; Malik M; Sohail S; Ali Z; Zahid F; Zeb A; Shah F; Yousaf A; Din F
Biomed Res Int; 2021; 2021():9968602. PubMed ID: 34285920
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles.
Ren T; Wang Q; Xu Y; Cong L; Gou J; Tao X; Zhang Y; He H; Yin T; Zhang H; Zhang Y; Tang X
J Control Release; 2018 Jan; 269():423-438. PubMed ID: 29133120
[TBL] [Abstract][Full Text] [Related]
11. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S; Mirza MA; Verma D; Khuroo T; Panda AK; Talegaonkar S; Khar RK; Iqbal Z
Drug Deliv; 2016 Oct; 23(8):2827-2837. PubMed ID: 26548664
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Qi X; Fan Y; He H; Wu Z
Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
[TBL] [Abstract][Full Text] [Related]
14. Entrapping of Nanoparticles in Yeast Cell Wall Microparticles for Macrophage-Targeted Oral Delivery of Cabazitaxel.
Ren T; Gou J; Sun W; Tao X; Tan X; Wang P; Zhang Y; He H; Yin T; Tang X
Mol Pharm; 2018 Jul; 15(7):2870-2882. PubMed ID: 29863879
[TBL] [Abstract][Full Text] [Related]
15. "Oil-soluble" reversed lipid nanoparticles for oral insulin delivery.
Wang T; Shen L; Zhang Y; Li H; Wang Y; Quan D
J Nanobiotechnology; 2020 Jul; 18(1):98. PubMed ID: 32680576
[TBL] [Abstract][Full Text] [Related]
16. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
17. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles.
Li H; Zhao X; Ma Y; Zhai G; Li L; Lou H
J Control Release; 2009 Feb; 133(3):238-44. PubMed ID: 18951932
[TBL] [Abstract][Full Text] [Related]
19. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
20. Labrasol-Enriched Nanoliposomal Formulation: Novel Approach to Improve Oral Absorption of Water-Insoluble Drug, Carvedilol.
Ghassemi S; Haeri A; Shahhosseini S; Dadashzadeh S
AAPS PharmSciTech; 2018 Oct; 19(7):2961-2970. PubMed ID: 30030724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
